GlassScriptPhysician profile
Thomas C Mcintosh
NPI 1750352688
$3,243.16
in general payments reported to CMS, 2019-2025
22 companies · $564 in 2025
The $564 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $173 · 2021: $382 · 2022: $682 · 2023: $519 · 2024: $405 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Entertainment: $15.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.96 |
| Entertainment | $15.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $822.97 | 2019-2025 | Total30, Precision7, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $438.99 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $379.38 | 2020-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $343.52 | 2022-2025 | Infuse, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $331.32 | 2019-2025 | Cequa |
| Coopervision INC. | $162.87 | 2019-2023 | Biofinity Contact Lens |
| Abbvie INC. | $123.37 | 2022 | |
| Horizon Therapeutics Plc | $114.57 | 2023 | Uplizna |
| Aerie Pharmaceuticals, INC. | $113.15 | 2019 | |
| Rxsight INC | $57.69 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Oyster Point Pharma, INC. | $53.13 | 2022-2025 | Tyrvaya, Ryzumvi |
| Genzyme Corporation | $46.34 | 2019-2022 | |
| Dompe US, INC. | $44.94 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $39.60 | 2024 | Xdemvy |
| Harrow Eye, LLC | $37.14 | 2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $28.73 | 2019-2022 | |
| Thea Pharma INC. | $26.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.52 | 2022 | |
| Optos, INC. | $15.53 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $15.25 | 2021 | |
| Notal Vision, INC. | $15.07 | 2024 | Foresee Home |
| Allergan, INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.